Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034

The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994

Miriam J. Alter, Deanna Kruszon-Moran, Omana V. Nainan et al. · New England Journal of Medicine · 1999 · 3K citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line

Volker Lohmann, Frank Körner, Jan Oliver Koch et al. · Science · 1999 · 2.8K citations

Life Sciences, Microbiology, Molecular Biology +16

Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo

Alexander A. Kolykhalov, Kathy Mihalik, Stephen M. Feinstone et al. · Journal of Virology · 2000 · 592 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +14

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

Robert B. Perni, Susan J. Almquist, Randal A. Byrn et al. · Antimicrobial Agents and Chemotherapy · 2006 · 387 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Discovery of 1-(4-Fluorophenyl)-(3<i>R</i>)-[3-(4-fluorophenyl)-(3<i>S</i>)- hydroxypropyl]-(4<i>S</i>)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235):  A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption

Stuart B. Rosenblum, Tram Huynh, Adriano Afonso et al. · Journal of Medicinal Chemistry · 1998 · 355 citations

Pharmacy, Medicinal Chemistry, Pharmacology +11